Bio-Thera Solutions, Biogen Publish Phase 3 Clinical Trial Data for TOFIDENCE, An Approved Biosimilar Referencing Tocilizumab In Arthritis Research & Therapy
Shanghai Fosun Pharmaceutical Reports 1H Results
Shanghai Pharmaceuticals Holding Co., Ltd Goes Ex Dividend on Monday
Ardelyx Announces Acceptance Of New Drug Application For Tenapanor For Hyperphosphatemia In China; Triggers $2M Milestone Payment To Ardelyx Under The Terms Of The License Agreement Between Co And Shanghai Fosun Pharmaceutical Industrial Development Co.
The FDA Clears C4 Therapeutics' Investigational New Drug Application For CFT8919 For Non-small Cell Lung Cancer; C4T Expects To Initiate Trials Outside Greater China After Betta Pharmaceuticals Concludes Phase 1 Dose Escalation Study In Greater China
Disc Medicine Announces Exclusive Licensing Agreement With Mabwell Therapeutics For Novel Anti-TMPRSS6 Monoclonal Antibodies To Modulate Iron Homeostasis; Mabwell To Receive $10M Upfront Payment And Up To $412.5M In Milestones